about
EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitorsThe sugar ring of the nucleoside is required for productive substrate positioning in the active site of human deoxycytidine kinase (dCK): implications for the development of dCK-activated acyclic guanine analoguesMechanism of activation of PSI-7851 and its diastereoisomer PSI-7977Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulationsHIV Genome-Wide Protein Associations: a Review of 30 Years of ResearchAn Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and ResistanceRole of Marine Natural Products in the Genesis of Antiviral AgentsNanostructures for the Inhibition of Viral InfectionsFrom the chemistry of epoxy-sugar nucleosides to the discovery of anti-HIV agent 4'-ethynylstavudine-FestinavirClass III Phosphatidylinositol 4-Kinase Alpha and Beta Are Novel Host Factor Regulators of Hepatitis C Virus ReplicationSerotype-Specific Structural Differences in the Protease-Cofactor Complexes of the Dengue Virus FamilySolution Structure of a Hydrocarbon Stapled Peptide Inhibitor in Complex with Monomeric C-terminal Domain of HIV-1 CapsidDiscovery of an allosteric mechanism for the regulation of HCV NS3 protein functionApproved Antiviral Drugs over the Past 50 YearsMolecular features related to HIV integrase inhibition obtained from structure- and ligand-based approachesNMR and MD Studies Reveal That the Isolated Dengue NS3 Protease Is an Intrinsically Disordered Chymotrypsin Fold Which Absolutely Requests NS2B for Correct Folding and Functional DynamicsFlipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel.Molecular docking of (5E)-3-(2-aminoethyl)-5-(2- thienylmethylene)-1, 3-thiazolidine-2, 4-dione on HIV-1 reverse transcriptase: novel drug acting on enzyme.Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plantsIdentification of oligopeptides mimicking the receptor-binding domain of Hantaan virus envelope glycoprotein from a phage-displayed peptide library.Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures.Inhibition of the ribonuclease H activity of HIV-1 reverse transcriptase by GSK5750 correlates with slow enzyme-inhibitor dissociation.Targeting protein-protein interactions for therapeutic intervention: a challenge for the future.Inhibition of highly pathogenic avian influenza (HPAI) virus by a peptide derived from vFLIP through its direct destabilization of viruses.Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitorsInferring proteolytic processes from mass spectrometry time series data using degradation graphs.Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replicationTherapeutics for filovirus infection: traditional approaches and progress towards in silico drug design.Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitorsDesign, synthesis, antiviral activity, and pre-formulation development of poly-L-arginine-fatty acyl derivatives of nucleoside reverse transcriptase inhibitors.HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition.HIV-1 modulates the tRNA pool to improve translation efficiency.Molecular dynamics simulations of viral RNA polymerases link conserved and correlated motions of functional elements to fidelityAntiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.Synthesis of new 2'-deoxy-2'-fluoro-4'-azido nucleoside analogues as potent anti-HIV agents.Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agentsTargeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase
P2860
Q24606095-A154858B-6BD8-4AF3-B8BB-B14798F1EA79Q24613258-CAE449D2-722C-482C-B77C-AE27DF45C803Q24621496-6C883D6B-7B9C-4C97-B052-8A01E248E971Q24654012-B0F4499C-7AF4-4473-94AD-00CD5C3B7EE9Q26746070-00725A55-722C-46BB-9D54-5590D6DA237AQ26771734-9758A39A-0C6C-4CD7-A072-191A0B5A9739Q26783056-4A137A37-7D35-42BA-A580-326E460A556DQ26796360-34128BB7-0251-463F-BA9E-6C1824CD4751Q26801513-BFEFB4AC-E97C-4696-B9CD-FF5451AD5650Q27010583-D18592AE-09EF-48D2-8806-0674FEB368C9Q27489697-E1897D12-AC6D-4254-BF9F-A792DB050611Q27490960-84A49693-BC40-4CD0-BA55-1AFBCAA7D0FAQ27650342-BE614950-1608-47E0-8E67-0B202E2FF211Q27673761-32506AC2-19AC-40A3-A757-8057C0341B97Q27755387-1DA05B47-9959-4D93-8F2D-FA09611B7B1BQ28538414-A5B0F393-C3D2-417B-8CB1-0A2AF71C9DF0Q28547136-76399E83-E3D7-4986-9287-E456C07D2063Q30369353-B6049BE6-6661-474A-B11F-A81A2B199D7CQ30422172-A880D573-FD91-421D-9F96-C185B497D4E1Q33490833-40AEECAE-FFBE-4212-9F51-8DE71B1F23AEQ33505195-5F3134C5-5E46-4D82-909C-23FD4C5B9B38Q33635679-97CD2CD6-0E04-480E-822E-31953A93F82EQ33718515-408641C0-5EC7-404E-8638-719C580DBD46Q33852396-5DF8E978-2F77-437E-820E-C06E909794EBQ33884759-71E31471-2134-400C-8BFB-C38F67E33E3BQ33892766-AF8547AC-CAB7-4B62-9EE4-E8BFF1889910Q34044221-4D9344AD-B6BC-4238-A5F7-BE63415FE7B9Q34344991-02A56978-8DC2-405D-B4A5-A8743BE456D3Q34361091-617B5F6E-7EBB-4E4E-9285-4725349B6FEDQ34371001-CF4333A0-36CB-46C7-A806-3490F80D7D6AQ34530512-8897FD3C-D451-4255-BA76-54FB48D196E1Q34723096-3EFB0ECC-69B9-4D80-9479-C4F9E566FE9DQ34849844-7714ADC0-3C1B-4DFC-9070-2D2C631A3C1BQ34994062-0CBCC589-F562-43CA-86DA-4E427C5420B8Q35042768-03705E1A-86B9-4C12-A4E9-9C09615CE539Q35139538-CE750D0F-0A3C-4599-8E0E-F87EB839A35EQ35190067-F30044F6-46B3-4A95-919D-B16EC6F1B6A6Q35673318-D45B5E4E-4C6E-490C-84C2-E51318DA8A0AQ35687836-5B28736C-4EBC-4EBA-93F6-779B0DF2BA41Q35753013-4DDB7BB3-C911-4AB1-9069-A60AA1F4F016
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The design of drugs for HIV and HCV
@ast
The design of drugs for HIV and HCV
@en
The design of drugs for HIV and HCV
@nl
type
label
The design of drugs for HIV and HCV
@ast
The design of drugs for HIV and HCV
@en
The design of drugs for HIV and HCV
@nl
prefLabel
The design of drugs for HIV and HCV
@ast
The design of drugs for HIV and HCV
@en
The design of drugs for HIV and HCV
@nl
P2860
P3181
P356
P1476
The design of drugs for HIV and HCV
@en
P2860
P2888
P304
P3181
P356
10.1038/NRD2424
P407
P577
2007-12-01T00:00:00Z